debate: is it appropriate to treat patients with cll earlier in the era of novel agents? - no
Published 7 years ago • 3.3K plays • Length 12:34Download video MP4
Download video MP3
Similar videos
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
16:26
debate: is cr and mrd negativity still required in the era of novel agents? - no
-
24:17
combination of novel agents in cll: is this the final answer?
-
15:02
debate: will novel-agent based combination therapy become standard of care for cll? - no
-
27:18
novel treatment options in cll
-
13:49
roger talks about living with cll
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
53:03
talk by professor paul moss - cll treatment in 2022/23
-
14:21
debate: which is the optimal approach for cll? - fcr
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
46:17
myeloma experts address new treatments, financial considerations, early detection, & management.
-
16:24
chemotherapy vs novel agents in young cll patients: is there still a role for chemo?
-
3:40
understanding the timing of therapy in cll
-
18:49
use of novel prognostic markers in practice for cll
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
12:45
debate: should maintenance rituximab be used in follicular lymphoma? - no
-
14:02
debate: is obinutuzumab superior to rituximab in lymphoma? - no
-
21:09
minimal residual disease (mrd) in cll: is it clinically relevant?
-
13:03
debate: hodgkin lymphoma patient who relapses after autologous sct - allogeneic sct
-
26:51
richter’s syndrome: risk, predictors, and treatment
-
12:53
selecting first-line treatment for chronic lymphocytic leukemia (cll)
-
27:28
risk assessment in cll treatment